⚠ Two Countries Are Most of ItModerate threat

AbbVie (ABBV) — threat to the moat

Most of AbbVie's cosmetics sales come from American and Chinese consumers paying cash, which makes the business move with their confidence.

Aesthetics is geographically concentrated. Management said the United States and China are a vast majority of the aesthetics business1. Both markets depend on consumers paying cash for elective treatments.

Botox Cosmetic net revenues, 2025 ($M)1,504United States1,098InternationalAbbVie Form 10-K FY2025
A consumer business in two markets.

That makes the business cyclical in a way AbbVie's prescription drugs are not. The 10-K attributes the American Botox Cosmetic decline partly to decreased consumer demand2, and China adds regulatory and economic risk on top.

Botox Cosmetic sold $1,504 million in the United States and $1,098 million internationally in 20253.

China adds a separate risk. A cash-pay consumer market in a country with its own regulators and competitors can shift quickly, and Botox Cosmetic is approved in China for masseter muscle prominence4, a use that shows how the market there differs.

The concentration also limits diversification. An aesthetics business spread across many countries would smooth out a weak year in one; one that depends on two moves with their consumers. Management's own description of the business as mostly American and Chinese5 makes that plain.

Aesthetics growth in the United States is the tell. Another year of decline would mean the business is shrinking with its consumers, not just resetting prices.

References
  1. ReportedManagement said the United States and China are a vast majority of the aesthetics business.
    The Motley Fool, AbbVie Q4 2025 earnings call transcript - 2026 revenue assumptions by product and management's comments on share and competitors. — Q4 2025 · publ. 4 February 2026 · source ↗
  2. ReportedThe 10-K attributes the American Botox Cosmetic decline partly to decreased consumer demand, and China adds regulatory and economic risk on top.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedBotox Cosmetic sold $1,504 million in the United States and $1,098 million internationally in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  4. ReportedA cash-pay consumer market in a country with its own regulators and competitors can shift quickly, and Botox Cosmetic is approved in China for masseter muscle prominence, a use that shows how the market there differs.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  5. ReportedManagement's own description of the business as mostly American and Chinese makes that plain.
    The Motley Fool, AbbVie Q4 2025 earnings call transcript - 2026 revenue assumptions by product and management's comments on share and competitors. — Q4 2025 · publ. 4 February 2026 · source ↗
Sources
Generated September 25, 2026